Neumora Therapeutics (NMRA) Change in Cash (2022 - 2026)

Neumora Therapeutics' Change in Cash history runs 5 years deep, the most recent figure standing at -$35.5 million for Q1 2026.

• In Q1 2026, Change in Cash fell 131.93% year-over-year to -$35.5 million; the TTM figure through Mar 2026 stood at $19.0 million (up 133.89% YoY), while the FY2025 annual figure was $39.2 million, up 116.89% from the prior year.
• Change in Cash was -$35.5 million for Q1 2026 at Neumora Therapeutics, down from $53.5 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $208.1 million in Q3 2023 to a low of -$191.1 million in Q1 2024.
• Historically, Change in Cash has averaged -$7.6 million across 5 years, with a median of -$13.4 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Change in Cash sank 534.44% in 2024, then jumped 140.02% in 2025.
• A 5-year view of Change in Cash shows it stood at -$11.6 million in 2022, then tumbled by 230.76% to -$38.2 million in 2023, then slumped by 249.23% to -$133.6 million in 2024, then surged by 140.02% to $53.5 million in 2025, then sank by 166.33% to -$35.5 million in 2026.
• The last three Change in Cash figures came in at -$35.5 million (Q1 2026), $53.5 million (Q4 2025), and $4.5 million (Q3 2025), per Business Quant data.